2μg (R: reducing condition).
Product Details
Product Details
Product Specification
| Species | Human |
| Accession | P05113 |
| Amino Acid Sequence | Ile20-Ser134, with N-His Tag |
| Expression System | HEK293 |
| Molecular Weight | Predicted MW: 14.8 kDa Observed MW: 17-23 kDa |
| Purity | >95% by SDS-PAGE |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | 0.2M PBS, pH7.4 with 3% trehalose. |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
Background
IL-5 is the predominant cytokine associated with antigen-induced eosinophilic inflammation in the lung. The activation of Th-2 cells leads to the production of IL-5. The pro-eosinophilic effects of IL-5 include: (1) enhanced replication and differentiation of eosinophilic myelocytes; (2) enhanced degranulation of eosinophils; (3) prolonged survival time of eosinophils: and (4) enhanced adhesion of eosinophils. The effects of IL-5 are mediated via the interaction of IL-5 with receptors (IL-5R) that are expressed on the eosinophil cell membrane. Intracellular signalling produced by occupation of the IL-5R by IL-5 occurs via the JAK-STAT system.
Picture
Picture
SDS-PAGE

ELISA

Immobilized Human IL-5 Protein, His Tag at 5 μg/mL (100 μL/well) can bind Human IL-5 R alpha / CD125 Protein, Fc Tag with EC50 of 13.4-16.6 ng/ml.
